344 results on '"Jiménez Yuste, Victor"'
Search Results
2. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials
3. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
4. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks
5. Inhibitors in Hemophilia B
6. Inhibitors in Hemophilia A
7. Pathophysiology of Hemophilia
8. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study
9. No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study
10. Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A
11. Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report
12. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies
13. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
14. Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage
15. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial
16. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
17. Haemophilia: Reasons for visits to the paediatric emergency department
18. Hemofilia: naturaleza de las visitas a urgencias pediátricas
19. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results
20. Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
21. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
22. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
23. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A—Final efficacy and safety results from the NuProtect study
24. Haemophilia B: Where are we now and what does the future hold?
25. A New Face of Fibrin-Associated Large B-Cell Lymphoma: Epstein–Barr Virus-Positive Breast Implant-Associated Diffuse Large B-Cell Lymphoma
26. Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
27. Hematological Concepts and Hematological Perioperative Treatment
28. The Analgesic Efficacy of a COX-2 Inhibitor (Oral Celecoxib) in Adult Hemophilic Patients and Intense Joint Pain Secondary to Advanced Hemophilic Arthropathy
29. Comparative analysis of Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) scores in persons with nonsevere hemophilia A and B reveals a high degree of joint damage in both disease types
30. Considerations for shared decision management in previously untreated patients with hemophilia A or B
31. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus
32. sj-docx-1-tah-10.1177_20406207231165857 – Supplemental material for Considerations for shared decision management in previously untreated patients with hemophilia A or B
33. Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report.
34. Immune Tolerance Induction in the Era of Emicizumab—Still the First Choice for Patients With Hemophilia A and Inhibitors?
35. Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
36. Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
37. Predictive Value of Platelet Sequestration Studies in Splenectomy Response
38. International consensus recommendations on the management of people with haemophilia B.
39. Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
40. sj-docx-1-tah-10.1177_20406207221085202 – Supplemental material for International consensus recommendations on the management of people with haemophilia B
41. PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors
42. International consensus recommendations on the management of people with haemophilia B
43. The factor VIII treatment history of non‐severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD‐US system
44. Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
45. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
46. Delivery of AAV-based gene therapy through haemophilia centres - a need for re-evaluation of infrastructure and comprehensive care: a Joint publication of EAHAD and EHC
47. Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
48. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa
49. Chilblain-like lesions and COVID-19 infection: A prospective observational study at Spain's ground zero
50. Switching treatments in haemophilia: is there a risk of inhibitor development?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.